胡开顺副研究员
中山大学孙逸仙纪念医院基础与转化医学研究中心
广东省“特支计划”科技创新青年拔尖人才。研究领域:从2009年开始至今一直从事蛋白翻译后修饰与肿瘤基因组不稳定性、细胞周期调控紊乱及肿瘤放化疗、靶向治疗耐受等方面的分子机制研究,在肿瘤发生发展及耐药机制等方向取得一系列重要的原创性成果,共发表20多篇相关的第一或通讯(含共同)SCI学术论文,其中包括6篇影响因子>10,包括Journal of Clinical Investigation、Advanced Science、Molecular Psychiatry 、EMBO Report、Oncogene、Signal Transduction and Targeted Therapy等;作为项目负责人获得4项国家自然科学基金项目资助(青年基金1项,面上项目3项),获批2项国家发明专利;Oncogene、Oncogenesis等期刊同行评议专家。联系方式:huksh3@mail.sysu.edu.cn,主持的部分基金项目:(1) 国家自然科学基金面上项目,82373150,2024/01-2027/12,48万元,在研,主持;(2) 国家自然科学基金面上项目,82172636,2022/01-2025/12,55万元,在研,主持;(3) 国家自然科学基金面上项目,81772821,2018/01-2021/12,52万元,已结题,主持;(4) 国家自然科学基金青年项目,81301732,2014/01-2016/12,23万元,已结题,主持;(5) 广东省特支计划“科技创新青年拔尖人才”项目,2021TQ06Y125,2022/11-2025/10,50万元,在研,主持;近五年代表性论文(#第一作者,*通讯作者):1、Kaishun Hu#(第一作者),Yu Li#,Wenjing Wu#,Limin Xie#,Haiyan Yan,Yuexin Cai,Dong Chen,Qiongchao Jiang,Lehang Lin,Zhen Chen,Jian-You Liao,Yin Zhang,H Phillip Koeffler,Dong Yin*,Erwei Song*,ATM-Dependent Recruitment of BRD7 is required for Transcriptional Repression and DNA Repair at DNA Breaks Flanking Transcriptional Active Regions,Adv Sci (Weinh). 2020 Sep 3;7(20):2000157. (IF: 17.5).,2、Kaishun Hu#(第一作者),Wenjing Wu#,Yu Li#,Lehang Lin,Dong Chen,Haiyan Yan,Xing Xiao,Hengxing Chen,Zhen Chen,Yin Zhang,Shuangbing Xu,Yabin Guo,H Phillip Koeffler,Erwei Song*,Dong Yin*,Poly(ADP-ribosyl)ation of BRD7 by PARP1 confers resistance to DNA-damaging chemotherapeutic agents,EMBO Rep. 2019 May;20(5): e46166. (IF: 9.0).,3、Wenjia Li#,Qingfang Han#,Yuanxin Zhu#,Yingshi Zhou#,Jingyuan Zhang,Weijun Wu,Yu Li,Long Liu,Yuntan Qiu,Kaishun Hu*(共同通讯作者),Dong Yin*,SUMOylation of RNF146 results in Axin degradation and activation of Wnt/β-catenin signaling to promote the progression of hepatocellular carcinoma. Oncogene. 2023 Apr 7. (IF: 8.7).,4、Fangfang Qi#,Zejie Zuo#,Kaishun Hu#(共同第一作者),Rui Wang,Tong Wu,Hao Liu,Jiaoling Tang,Qingbo Wang,Yufeng Xie,Liren Tan,Yunjie Yang,Xiaoran Zhang,Jiaying Zheng,Jie Xu,Zhibin Yao,Shengwen Wang*,Long-Jun Wu*,Kaihua Guo*,VEGF-A in serum protects against memory impairment in APP/PS1 transgenic mice by blocking neutrophil infiltration. Mol Psychiatry. 2023 Jun 6. (IF: 13.4).,5、Yang Yang#,Yuedong Ma#,Huabin Gao#,Tingsheng Peng,Huijuan Shi Yunxiang Tang,Hui Li,Lin Chen,Kaishun Hu*(共同通讯作者),Anjia Han*,A novel HDGF-ALCAM axis promotes the metastasis of Ewing sarcoma via regulating the GTPases signaling pathway. Oncogene. 2021 Jan;40(4):731-745. (IF: 8.7).,6、Liwen Zhou#,Lisi Zheng#,Kaishun Hu#(共同第一作者),Xin Wang,Ruhua Zhang,Yezi Zou,Li Zhong,Shang Wang,Yuanzhong Wu*,Tiebang Kang*,SUMOylation stabilizes hSSB1 and enhances the recruitment of NBS1 to DNA damage sites. Signal Transduct Target Ther. 2020 Jun 24;5(1):80. (IF: 38.4).,7、Kaishun Hu#(第一作者),Yu Li#,Wenjing Wu#,Hengxing Chen,Zhen Chen,Yin Zhang,Yabin Guo*,Dong Yin*. High-performance gene expression and knockout tools using sleeping beauty transposon system,Mob DNA. 2018 Nov 26; 9:33. (IF: 4.6),8、Wenjing Wu#,Jianli Zhao#,Jianhong Xiao,Weijun Wu,Limin Xie,Xiaojuan Xie,Chaoye Yang,Dong Yin*,Kaishun Hu*(通讯作者). CHFR-mediated degradation of RNF126 confers sensitivity to PARP inhibitors in triple-negative breast cancer cells,Biochem Biophys Res Commun. 2021 Oct 8;573: 62-68. (IF:3.5),9、Yu Li#,Kaishun Hu#(共同第一作者),Xing Xiao,Wenjing Wu,Haiyan Yan,Hengxing Chen,Zhen Chen,Dong Yin*. FBW7 suppresses cell proliferation and G2/M cell cycle transition via promoting γ-catenin K63-linked ubiquitylation,Biochem Biophys Res Commun. 2018 Mar 4;497(2):473-479. (IF:3.5),10、Yu Li#,Xing Xiao#,Hengxing Chen,Zhen Chen,Kaishun Hu*(共同通讯作者),Dong Yin*. Transcription factor NFYA promotes G1/S cell cycle transition and cell proliferation by transactivating cyclin D1 and CDK4 in clear cell renal cell carcinoma,Am J Cancer Res. 2020 Aug 1;10(8):2446-2463. (IF:5.9),11、Yumei Huang#,Kaishun Hu#(共同第一作者),Sheng Zhang#,Xiaorong Dong,Zhongyuan Yin,Rui Meng,Yingchao Zhao,Xiaofang Dai,Tao Zhang,Kunyu Yang,Li Liu,Kai Huang,Shaojun Shi,Yu Zhang,Junjie Chen,Gang Wu*,Shuangbing Xu*. S6K1 phosphorylation-dependent degradation of Mxi1 by β-Trcp ubiquitin ligase promotes Myc activation and radioresistance in lung cancer,Theranostics. 2018 Feb 2;8(5):1286-1300. (IF:11.6),12、Zhen Chen#,Wenjing Wu#,Yongsheng Huang,Limin Xie,Yu Li,Hengxing Chen,Wenjia Li,Dong Yin*,Kaishun Hu*(通讯作者). RCC2 promotes breast cancer progression through regulation of Wnt signaling and inducing EMT. J Cancer. 2019 Nov 1;10(27):6837-6847. (IF:4.4),13、Hengxing Chen#,Yun Li#,Yu Li,Zhen Chen,Limin Xie,Wenjia Li,Yuanxin Zhu,Hong Xue,H Phillip Koeffler,Wenjing Wu,Kaishun Hu*(共同通讯作者),Dong Yin*. PARK2 promotes mitochondrial pathway of apoptosis and antimicrotubule drugs chemosensitivity via degradation of phospho-BCL-2. Theranostics. 2020 Aug 8;10(22):9984-10000. (IF:11.6)